Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
about
Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.MET signaling promotes DNA repair and radiation resistance in glioblastoma stem-like cells.Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas.MET/SMAD3/SNAIL circuit mediated by miR-323a-3p is involved in regulating epithelial-mesenchymal transition progression in bladder cancer.MET: roles in epithelial-mesenchymal transition and cancer stemness.Integrating RNA sequencing into neuro-oncology practice.Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas.PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma.confFuse: High-Confidence Fusion Gene Detection across Tumor Entities.Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma.TumorFusions: an integrative resource for cancer-associated transcript fusions.Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter-hypermethylation - the NCT Neuro Master Match (N2M2) pilot study.The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.TFG-MET fusion in an infantile spindle cell sarcoma with neural features.Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers.Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas.Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells.Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment.Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors
P2860
Q34552042-0BE99B67-5E78-4468-9D0C-8B56C0E2A329Q37666955-08AF3460-3F5B-44EF-92BF-16A3D55DAF2BQ37698352-DA5D7B23-D802-4390-8AE2-5E4AF0B60411Q38694277-D2977FD3-58F7-4A13-95A2-DD7CBEB4FDE3Q39121333-3E47F841-34B7-407D-A65C-D0D0158CF6A7Q39459649-1E363D99-0EDF-4E50-BB76-C38C33BA1082Q41243504-43CC9582-B3BF-49E0-A4D8-5A435C5B691EQ41286737-DB6D3435-6988-4FEF-9818-9EE0EF31CE60Q42370080-4A7EDD99-64D5-4AC5-9FFB-16CD9ABBF82DQ42375231-568DA83B-9269-4AAE-A0C9-4AA2438CC076Q47207132-22EEC5D2-D08B-4453-AA64-2515E6D34829Q47374036-4C2F6A54-A3BD-42DF-AF7F-A99864895CFFQ47786514-E9013903-A164-40F5-BDC8-CD11B7AC6345Q48136767-AD5FAD5F-3630-4227-8BB1-1699052846C3Q49887893-8970B46F-28BF-4300-8DDE-CE980A39F230Q50733824-E71FE49F-A7C4-4D3C-ABF9-CA878D636970Q54113061-E57FA585-31F4-4C41-A8D1-F694B8468281Q55456542-C4C72546-2689-46D0-B07A-5054EC82E427Q55456561-DB52CE50-B30F-472B-897C-37845E1C7F3FQ55457412-C5ABB9FC-903F-49D9-9D74-99DE17881729Q59133452-4D0C3E90-42B8-4F4F-821B-2975BA8CBFBF
P2860
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
@en
type
label
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
@en
prefLabel
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
@en
P2860
P356
P1433
P1476
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
@en
P2093
International Cancer Genome Consortium PedBrain Tumor Project
P2860
P2888
P304
P356
10.1038/NM.4204
P407
P577
2016-10-17T00:00:00Z